Key result
Oxprenolol matches methyldopa and spironolactone for BP lowering but wins on tolerability with ~5% withdrawal.
Why the study?
Do oxprenolol, methyldopa, and spironolactone effectively lower blood pressure in patients with essential hypertension across different renin subgroups?
RCT (n=102)
Double-blind
Do oxprenolol, methyldopa, and spironolactone effectively lower blood pressure in patients with essential hypertension across different renin subgroups?
Oxprenolol, methyldopa, and spironolactone are equally effective at lowering blood pressure in essential hypertension regardless of baseline renin levels, but oxprenolol is the best tolerated.
Oxprenolol matches methyldopa and spironolactone for BP reduction with superior tolerability; confirms renin-independent efficacy and supports its preference in essential hypertension.
Plasma renin activity (PRA), supine, erect and post-frusemide (1 mg/kg IV) was studied in 51 patients with previously untreated essential hypertension and their age- and sex-matched normotensive controls. Supine PRA, and the rise in PRA in response to the erect posture and frusemide, were significantly less in hypertensives compared to controls. When the hypertensives were arbitrarily divided into lower, mid, and upper subgroups according to supine PRA, the renin responsiveness was similar in each subgroup but significantly less in hypertensives compared to controls, subdivided in the same way. This does not support the existence of a separate "low renin" subgroup. The low supine PRA and reduced response to stimulation appears to be a feature of patients with essential hypertension. Thirty-nine of these hypertensives entered a double-blind cross-over drug trial of oxprenolol, methyldopa and spironolactone. All three drugs were equally effective in lowering the systolic and diastolic blood pressures in all three renin subgroups. Spironolactone caused a greater fall in systolic pressure in the lower renin group than in the other groups. Oxprenolol was the best tolerated drug, with only 5% of patients withdrawing due to side-effects compared to 13% on spironolacone and 29% on methyldopa.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (1976) conducted an RCT in Essential hypertension (n=102). Oxprenolol, methyldopa, and spironolactone vs. Cross-over comparison was evaluated on Blood pressure lowering and withdrawal due to side-effects. Oxprenolol, methyldopa, and spironolactone equally lowered blood pressure, but oxprenolol was best tolerated (5% withdrawal vs 13% for spironolactone and 29% for methyldopa).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: